© header image: Tobias Wuestefeld
The Haas group develops and applies novel multimodal single-cell and spatially-resolved technologies to study the complex etiology of hematological cancers and their interaction with the immune system. Another key objective of the research group is the development of next-generation precision diagnostic and prognostic technologies, based on high-content single-cell multi-omics technologies.
These newly developed technologies aim at enabling early disease detection, highly precise, personalized treatment decisions and, ultimately, therapeutic intervention before disease onset.